MedX Health Announces Clinic and Mobile Dermatological Screening Services Partnership in New Brunswick

MedX Health with Sheppard Chiropractic opens in New Brunswick, with expansions initiatives underway for Atlantic Canada

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce a new regional partnership in New Brunswick, Canada. MedX Health has partnered with Dr. Jeff Sheppard in Saint John, New Brunswick to offer MedX’s DermSecure^® skin screening services in both Saint John and in underserved smaller communities in New Brunswick. The services will be offered both in established clinics and as a mobile service on a regular schedule to smaller communities in New Brunswick, and expanding to other provinces in Atlantic Canada.

“Dr. Sheppard is a very experienced clinician and business owner in New Brunswick and we are pleased to commence this bricks and mortar and mobile service in New Brunswick,” stated Paul Ziemer, VP of North American Sales.” Ziemer also added, “Our vision of delivering DermSecure to the greatest number of patients must include a mobile element, and this allows the underserved areas in New Brunswick to receive the same health care as the more populated communities.”

Sheppard Chiropractic Clinics now offering MedX Health Dermatological Screening Services:

• Head office: 168 Rothesay Ave, Saint John, New Brunswick (Tel: [phone])
  • 2 Chiropractors on staff
  • Multiple Allied Health Professionals on staff
  • High Volume Clinical Practice with focus on pain management & leading-edge health technologies
  • Retail locations offering Telemedicine, Orthotics, Compression wear and Body Bracing products

MedX continues to focus on expanding its DermSecure^® Screening Platform network across North America. To date, its business model has been focused on adding multiple market verticals, such as Medical Clinic/Building Hubs, Medical Scanning Clinics, Mobile and Remote Medical Practices, Esthetics and Skin Care Clinics.

"MedX is focused on growing its footprint into new and existing target markets, and our team continues to develop and accelerate many new commercial relationships and partnerships," stated Mike Druhan, MedX President, Dermatology Services. "I remain excited about our teams progress and ability to expand MedX's teledermatology platform into new jurisdictions and greatly improve outcomes for those dermatology patients seeking high-quality, virtual services."

Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy^®, and its secure, cloud-based patient management system, DermSecure^®, which transmits and stores patient data throughout the assessment process.

MedX's SIAscopy^® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin's surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours.

About MedX Health Corp.:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy^® on DermSecure^® telemedicine platform, utilizing its SIAscopy^® technology. SIAscopy^® is also imbedded in its products SIAMETRICS^®, SIMSYS^®, and MoleMate^®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS^®, SIMSYS^®, and MoleMate^® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.